The role of prophylaxis in bleeding disorders

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 189-193

  Berntorp, E ^a   De Moerloose, P ^b   Ljung, R C R ^a  

^a LUND UNIVERSITY   (Sweden)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Factor IX; Factor VIII; Haemophilia; Prophylaxis; Rare bleeding disorders; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; PROTHROMBIN; VITAMIN K GROUP; VON WILLEBRAND FACTOR;

ARTHROPATHY; BLEEDING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FAMILY HISTORY; HEMARTHROSIS; HEMOPHILIA; HUMAN; LONG TERM CARE; MORBIDITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; SUBSTITUTION THERAPY; THROMBOSIS; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIII; FACTOR X; HEMORRHAGE; HUMANS; QUALITY OF LIFE; VON WILLEBRAND DISEASES;

EID: 77955025580     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02319.x     Document Type: Review

References (15)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
2. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005, 16(Suppl. 1):S23-6.
3. Berntorp E, Abshire T. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006, 4:2511-2.
4. Nilsson IM. Von Willebrand's disease - fifty years old. Acta Med Scand 1977, 201:497-508.
5. Feldman BM, Pai M, Rivard GE. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006, 4:1228-36.
6. Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009, 35:349-55.
7. Bolton-Maggs PH, Perry DJ, Chalmers EA. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004, 10:593-628.
8. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006, 4:1634-7.
9. Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009, 15:990-1005.
10. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
11. van den Berg HM, Fischer K, Mauser-Bunschoten EP. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001, 112:561-5.
12. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994, 236:391-9.
13. Fischer K, van der Bom JG, Molho P. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-52.
14. Steen Carlsson K, Hojgard S, Glomstein A. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003, 9:555-66.
15. Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002, 20:759-74.